CERT: FDA PBPK Acceptance And Biosimulation Wins Will Support Future Core Relevance

Analysts have revised Certara's fair value estimate, with the updated price target modestly lower as they incorporate reduced assumptions for revenue growth and profit margins, along with a substantially higher expected future P/E multiple.

Analyst Commentary

Recent Street research on Certara has turned more cautious, with multiple firms cutting price targets and several moving to more neutral ratings. The changes largely reflect questions around growth visibility, execution under new leadership, and how much investors are willing to pay for the shares relative to current fundamentals.

Bullish Takeaways

Bullish analysts still see Certara as "uniquely positioned" in model-informed drug development, which they view as a supportive long term driver for the business and a key part of the equity story.
Several firms that reduced price targets chose to maintain positive or Buy ratings, suggesting they view recent headwinds as reflected in current valuation rather than a permanent impairment to the business model.
The updated targets, clustered around US$8 to US$10, indicate that some analysts still see potential upside from lower levels if management can improve consistency in software bookings and services performance.
Analysts maintaining constructive views appear focused on the idea that, with appropriate investment across the business, Certara could improve its growth profile over time, which would be supportive for P/E multiples.

Bearish Takeaways

Bearish analysts point to a "mediocre quarter" with a Q4 services miss and deceleration in software bookings, which raises concerns about execution and the reliability of medium term growth plans.
Several downgrades to Hold or Equal Weight, alongside cuts to price targets from levels such as US$16 to around US$8 to US$10, signal reduced confidence that Certara can quickly return to higher growth that would justify previous valuation levels.
Commentary citing "poor" management communication and the "absence of strategic plan" adds to uncertainty around how the new CEO will prioritize investments to improve core growth, which matters for both earnings power and market confidence.
Some research highlights that the 2026 outlook is below prior expectations and that the market is offering limited valuation support for this type of business today, which keeps pressure on Certara to deliver clearer execution milestones before sentiment improves.

What's in the News

Certara's physiologically based pharmacokinetic (PBPK) modeling, using the Simcyp Simulator, was accepted by the U.S. FDA in lieu of certain clinical studies to support the new drug application for asciminib (Scemblix). This helped replace at least ten dedicated clinical pharmacology studies and supported regulatory approval for a new treatment for Chronic Myeloid Leukemia (Key Developments).
The PBPK modeling for asciminib supported assessments across diverse patient populations, dosing regimens, and clinical scenarios, including potential drug interactions and differences between healthy volunteers and cancer patients (Key Developments).
Certara issued full year 2026 earnings guidance, indicating expected revenue growth in a range of 0% to 4% (Key Developments).
Between October 1, 2025 and December 31, 2025, Certara repurchased 344,697 shares for US$3.93 million, bringing total repurchases under the April 14, 2025 buyback to 3,368,374 shares for US$41.01 million (Key Developments).

Valuation Changes

Fair Value: The updated fair value estimate shifted from $8.99 to $8.71, a modest reduction in the modeled intrinsic value per share.
Discount Rate: The discount rate moved slightly from 9.18% to 9.12%, indicating only a minimal change in the assumed risk profile.
Revenue Growth: Revenue growth assumptions were reduced from about 5.07% to 3.85%, reflecting a more conservative outlook for top line expansion.
Net Profit Margin: Net profit margin expectations moved from roughly 5.97% to 2.16%, a significant reset in the earnings power assumed in the model.
Future P/E: The future P/E multiple increased from about 60.5x to roughly 167.3x, a very large step up that places more weight on long term earnings potential relative to current estimates.

5 views

Key Takeaways

Regulatory approvals and industry trends are boosting demand for Certara's biosimulation platforms, expanding its market and supporting stronger revenue streams.
Product innovation, strategic acquisitions, and cloud-based SaaS models increase customer retention, cross-selling, and margins, enhancing long-term profitability and earnings stability.
Certara's growth and profitability face risks from slow pharma adoption, reliance on large customers, rising costs, regulatory uncertainty, and possible delays in achieving returns from technology investments.

Catalysts

About Certara

Provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The recent qualification of Certara's Simcyp platform by the European Medicines Agency sets it apart as the only PBPK modeling tool with such approval, likely to increase customer adoption among global pharma companies seeking regulatory certainty and speed for their drug approvals, supporting future revenue growth.
Strong industry and regulatory momentum-such as the FDA's guidance to phase out animal testing in monoclonal antibody development-are rapidly increasing the need for biosimulation and model-informed drug development, expanding Certara's addressable market and driving sustained demand, positively impacting both revenues and bookings.
The upcoming commercial launch of Certara's next-generation, AI-enabled MIDD platform and CertaraIQ QSP software leverages advanced analytics and machine learning, providing differentiated capabilities that democratize access and increase the potential customer base, which should translate to higher recurring revenue and margin expansion through cloud-based SaaS models.
Integration of newly acquired businesses (like Applied BioMath and Formedix), combined with more robust cross-selling between consulting and software offerings, positions Certara to drive higher deal sizes and improve operating leverage, which strengthens both net margins and operating income over time.
Investment in cloud-based delivery and ongoing product innovation (as shown with updates to Phoenix and Pinnacle21 suites) further enhances customer stickiness and predictability of subscription revenue, supporting gross margin stability and long-term earnings growth.

Certara Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Certara's revenue will grow by 3.9% annually over the next 3 years.
Analysts assume that profit margins will increase from -0.4% today to 2.2% in 3 years time.
Analysts expect earnings to reach $10.2 million (and earnings per share of $0.07) by about April 2029, up from -$1.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $32.7 million in earnings, and the most bearish expecting $-9.8 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 167.5x on those 2029 earnings, up from -607.5x today. This future PE is greater than the current PE for the US Healthcare Services industry at 30.5x.
Analysts expect the number of shares outstanding to decline by 1.91% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.12%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The company faces potential headwinds from pharmaceutical industry cost containment, large pharma customer caution, and increased geopolitical and macroeconomic uncertainty-factors (including proposed tariffs and new pricing algorithms) that could delay decision-making and depress R&D budgets, which would negatively impact Certara's revenue and bookings growth in the long term.
Certara's R&D and operational spending has been increasing, with significant discretionary investments in software development, AI, and new product launches, and with the integration of multiple recent acquisitions. If these investments fail to generate expected adoption or ROI, operating expenses and margin pressure could undermine net earnings and profitability.
The company's continued growth depends heavily on adoption of new technologies (AI-enabled platforms, next-generation QSP products, etc.) and regulatory acceptance; any delays, low market uptake, or challenges in convincing regulators to integrate AI with model-informed drug development could slow software growth and diminish future revenues.
Although there is optimism about the multibillion-dollar addressable market for biosimulation (especially due to moves like the FDA's push to phase out animal testing), the adoption curve in pharma is often slow and complex, with many customers only piloting or cautiously expanding platform use-if customer education, regulatory clarity, or adoption stalls, bookings and revenue growth may not materialize as quickly as projected, affecting long-term earnings.
Certara's top-line and financial performance remains exposed to customer tier concentration; softness or timing issues from large Tier 1 customers can cause significant volatility in bookings and renewal cycles, making revenue less predictable and increasing risk to both revenue consistency and operating margins if consolidation or budget reductions occur among top clients.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $8.71 for Certara based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $11.0, and the most bearish reporting a price target of just $6.35.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $469.2 million, earnings will come to $10.2 million, and it would be trading on a PE ratio of 167.5x, assuming you use a discount rate of 9.1%.
Given the current share price of $6.32, the analyst price target of $8.71 is 27.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Certara?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Maintain Certara Price Target as Pharma Sector Recovery and New Developments Drive Outlook